Salivary duct carcinoma （SDC）, which originates mainly from the parotid gland, is liable to develop distant metastasis at an early phase. It is an extremely malignant cancer occurring on the head and neck, for which radiotherapy and chemotherapy are generally not effective. One characteristic is its expression of the androgen receptor （AR）; endocrine therapy targeting the AR would be effective for SDC. Although therapy targeting the AR is used for prostate cancer, it is not indicated for head and neck cancer. In our department, maximal androgen blockade therapy （MAB; usually used for prostate cancer） has been adopted since 2012 for cases of AR-positive advanced SDC for which first-line chemotherapy and radiotherapy were ineffective. MAB therapy showed three complete responses, one partial response and one disease progression as the best response of the target lesion in SDC patients with distant metastasis. Further, the therapy may contribute to the extension of life prognosis. MAB therapy is safe and effective for advanced SDC.